Showing results (1-10 of 161) with videos related to
Sort By:
Pageof 17
Biological Psychiatry|October 6, 1997
Recent and remote memory dissociation: medication effects and hippocampal function in schizophreniaM W Gilbertson, D P van KammenThe American Journal of Psychiatry|March 1, 1994
CSF dopamine beta-hydroxylase in schizophrenia: associations with premorbid functioning and brain computerized tomography scan measuresD P van Kammen, M E Kelley, M W Gilbertson, et al.Biological Psychiatry|June 1, 1993
Electroencephalographic sleep in clinically stable schizophrenic patients: two-weeks versus six-weeks neuroleptic-freeE A Nofzinger, D P van Kammen, M W Gilbertson, et al.Archives of General Psychiatry|August 1, 1995
Behavioral vs biochemical prediction of clinical stability following haloperidol withdrawal in schizophreniaD P van Kammen, M E Kelley, J A Gurklis, et al.Schizophrenia Research|May 3, 1997
Chronic haloperidol treatment does not affect structure of attention in schizophreniaD N Allen, M W Gilbertson, D P van Kammen, et al.Psychological Medicine|November 1, 1991
The biochemical basis of relapse and drug response in schizophrenia: review and hypothesisD P van KammenThe American Journal of Psychiatry|February 1, 1977
gamma-Aminobutyric acid (Gaba) and the dopamine hypothesis of schizophreniaD P Van KammenNeuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 1, 1996
Predicting duration of clinical stability following haloperidol withdrawal in schizophrenic patientsD P van Kammen, M E Kelley, J A Gurklis, et al.Psychiatry Research|April 1, 1992
CSF chromogranin A-like immunoreactivity in schizophrenia: relationships with REM latency and slow wave sleepD P van Kammen, D T O'Connor, T C Neylan, et al.Clinical Neuropharmacology|January 1, 1990
Are biochemical markers for treatment-resistant schizophrenia state dependent or traits?D P van Kammen, N SchoolerPageof 17